共 50 条
- [21] Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination ( vol 41, 1 , pg-75 , 2023 ) JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) : 2454 - 2454
- [26] IN VITRO STUDY OF PHLORETIN-INDUCED CELL DEATH EFFECTS IN HUMAN LIVER CANCER CELLS THROUGH INHIBITION OF TYPE II GLUCOSE TRANSPORTER RECENT ADVANCES IN FOOD AND FLAVOR CHEMISTRY: FOOD FLAVORS AND ENCAPSULATION, HEALTH BENEFITS, ANALYTICAL METHODS, AND MOLECULAR BIOLOGY OF FUNCTIONAL FOODS, 2010, : 400 - +
- [27] Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study JAAD INTERNATIONAL, 2021, 5 : 112 - 120